The present study screened riboflavin mimicking small molecules to determine their binding activity for the riboflavin binding protein. We performed thermodynamic and kinetic binding studies of these molecules using a combination of two analytical approaches; isothermal titration calorimetry and surface plasmon resonance spectroscopy. Screening of a biased set of non-riboflavin based small molecules by microcalorimetry led to the discovery of two known drug molecules, quinacrine and chloroquine, as favorable ligands for the riboflavin receptor with K(D) value of 264, and 2100 nM, respectively. We further demonstrated that quinacrine is a competitive ligand for the receptor as measured by surface plasmon resonance. Thus this study describes the identification of a novel class of dual acting riboflavin antagonists that target riboflavin receptor for cellular uptake and display multifunctional activities upon cellular entry.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114641PMC
http://dx.doi.org/10.1021/ml100296zDOI Listing

Publication Analysis

Top Keywords

riboflavin antagonists
8
thermodynamic kinetic
8
small molecules
8
surface plasmon
8
plasmon resonance
8
riboflavin receptor
8
riboflavin
6
bioanalytical screening
4
screening riboflavin
4
antagonists targeted
4

Similar Publications

This study represents the first investigation into the ultrasonic and microwave extraction of bioactive metabolites from (red seaweed) and () (brown seaweed), with a focus on their biological activities. The research compares ultrasound-assisted extraction (UAE) with microwave-assisted extraction (MAE) utilizing a hydromethanolic solvent to evaluate their effects on these seaweeds' bioactive compounds and biological activities. The assessment included a series of antioxidant essays: DPPH, ABTS, phenanthroline, and total antioxidant capacity, followed by enzyme inhibition activities: alpha-amylase and urease.

View Article and Find Full Text PDF

Endogenous plasma riboflavin is not a viable BCRP biomarker in human.

Clin Transl Sci

December 2024

Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.

Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co-administration of 375 mg once daily (q.

View Article and Find Full Text PDF

Riboflavin (vitamin B) has been proposed as a biomarker for breast cancer resistance protein (BCRP) activity. In recent studies in mice, cynomolgus monkeys, and humans, BCRP-inhibiting drugs increased the plasma concentration of riboflavin. We showed recently that ticagrelor inhibits BCRP and raises the plasma concentrations of the BCRP substrate rosuvastatin in healthy volunteers.

View Article and Find Full Text PDF

Mining the Dynamical Properties of Substrate and FAD Binding Pockets of LSD1: Hints for New Inhibitor Design Direction.

J Chem Inf Model

June 2024

Key Lab of Advanced Drug Preparation Technologies, Ministry of Education of China, State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, Henan 450001, China.

Lysine-specific demethylase 1 (LSD1), a highly sophisticated epigenetic regulator, orchestrates a range of critical cellular processes, holding promising therapeutic potential for treating diverse diseases. However, the clinical research progress targeting LSD1 is very slow. After 20 years of research, only one small-molecule drug, BEA-17, targeting the degradation of LSD1 and CoREST has been approved by the U.

View Article and Find Full Text PDF
Article Synopsis
  • Tuberculosis (TB) remains a serious global health issue, highlighting the need for new treatments, especially against drug-resistant strains.
  • This study focuses on lumazine synthase (RibH) as a key drug target for fighting Mycobacterium tuberculosis (M. tb), validating this approach using a CRISPRi gene knockdown strategy and high-throughput screening of over 600,000 compounds.
  • Three identified compounds show strong antimycobacterial effects, reduce M. tb burden, enhance the effects of existing anti-TB drugs, and display favorable safety profiles, making RibH a promising target for future TB treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!